Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Tiacci E, et al. Among authors: ferrari s. N Engl J Med. 2021 May 13;384(19):1810-1823. doi: 10.1056/NEJMoa2031298. N Engl J Med. 2021. PMID: 33979489 Clinical Trial.
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.
Rigacci L, Annibali O, Kovalchuk S, Bonifacio E, Pregnolato F, Angrilli F, Vitolo U, Pozzi S, Broggi S, Luminari S, Merli F, Spina M, Bolis S, Margiotta-Casaluci G, Scalzulli R, Cox C, Mamusa AM, Santoro A, Zinzani PL, Ferrari S, Gini G, Vigliotti ML, Mulè A, Flenghi L; Fondazione Italiana Linfomi (FIL). Rigacci L, et al. Among authors: ferrari s. Hematol Oncol. 2020 Oct;38(4):478-486. doi: 10.1002/hon.2764. Epub 2020 Jul 9. Hematol Oncol. 2020. PMID: 32542788 Free PMC article.
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A. Gay F, et al. Among authors: ferrari s. Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. Blood. 2013. PMID: 23775712 Free article. Clinical Trial.
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M, Giustini V, Facchetti GV, Roccaro AM, Ferrari S, Peli A, Bottelli C, Cattaneo C, Crippa C, Micilotta M, Frittoli B, Grazioli L, Rossi G, Tucci A. Belotti A, et al. Among authors: ferrari s. Cancer Med. 2021 Sep;10(17):5859-5865. doi: 10.1002/cam4.4136. Epub 2021 Jul 15. Cancer Med. 2021. PMID: 34263564 Free PMC article.
Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study.
Re A, Ferrari S, Frata P, Pizzocaro C, Crippa C, Tucci A, Facchetti F, Grazioli L, Magrini SM, Rossi G. Re A, et al. Among authors: ferrari s. Ann Oncol. 2008 May;19(5):951-7. doi: 10.1093/annonc/mdm596. Epub 2008 Jan 21. Ann Oncol. 2008. PMID: 18209012 Free article. Clinical Trial.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, Bottelli C, Cattaneo C, Tucci A, De La Fuente Barrigon C, Rossi G. Belotti A, et al. Among authors: ferrari s. Am J Hematol. 2020 Jul;95(7):759-765. doi: 10.1002/ajh.25797. Epub 2020 Apr 23. Am J Hematol. 2020. PMID: 32242970 Free article. Clinical Trial.
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G. D'Adda M, et al. Among authors: ferrari s. Cancer. 2019 May 15;125(10):1674-1682. doi: 10.1002/cncr.31977. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707758 Free article.
An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.
Schieppati F, Balzarini P, Fisogni S, Re A, Pagani C, Bianchetti N, Micheli L, Passi A, Ferrari S, Maifredi A, Bottelli C, Leopaldo R, Pellegrini V, Facchetti F, Rossi G, Tucci A. Schieppati F, et al. Among authors: ferrari s. Haematologica. 2020 May;105(5):1369-1378. doi: 10.3324/haematol.2019.223891. Epub 2019 Aug 8. Haematologica. 2020. PMID: 31399522 Free PMC article.
2,600 results